Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2006

View Archived Issues

Takeda presents a year of highlights

Matuzumab-paclitaxel combination feasible, active in non-small cell lung cancer

Lolitrems from endophytic fungus inhibit proinflammatory cytokine response

Studies suggest potential of anti-CD200 therapy for cancer

Combination therapy with lumiliximab evaluated in chronic lymphocytic leukemia

Enrollment under way in phase IIb study of Fentanyl Taifun

KaloBios creates engineered human antibody therapeutic for Novartis

NIH opens phase I study of MedImmune's attenuated, intranasal H5N1 vaccine

Photoprotective CUV-1647 increases melanin density in fair-skinned subjects

Topline findings for Testim in patients with type 2 diabetes

FDA clearance for VITROS NT-proBNP assay

PPL-100 shows potential as once-daily protease inhibitor

Atugen signs collaborations for manufacture and formulation of Atu-027

Sapacitabine begins phase I study in advanced leukemias

First Horizon stockholders approve name change to Sciele Pharma

Phase III MRSA study of Aurograb completes enrollment

Efficacy and safety of the selective 5-HT2C agonist lorcaserin shown in obese men and women

CVT-3619 decreases fasting plasma glucose and improves insulin sensitivity in ZDF rats

Pharmacokinetics, tolerability and efficacy for cetilistat in healthy and diabetic obese subjects

Synera topical anesthetic patch now available

Cisplatin analogue displays improved antitumor activity in colon cancer cells compared to cisplatin

Telomerase inhibitor GRN-163L prevents tumor growth and metastasis of breast cancer in vivo

Efficacy of the TLR9 agonist IMO-2055 in lung cancer models

Camptothecin antitumor activity can be enhanced by NIK-12192, an inhibitor of vacuolar H+-ATPase

New anticoagulants disclosed in recent patents

BioXell and Universite Henri Poincare jointly report TREM-1 inhibitors for sepsis

New agents imparted for the treatment of arthritis and other inflammatory disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...